Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells

Area of Science:

• Molecular Biology
• Cell Biology
• Cancer Research

Background:

• Multiple myeloma (MM) cells produce monoclonal protein (MP), and disrupting the isoprenoid biosynthetic pathway (IBP) blocks MP secretion, inducing apoptosis.
• Autophagy, a cellular degradation process, is triggered by stressors like ER stress, and IBP inhibitors show varied effects on it.

Purpose of the Study:

• To elucidate the mechanisms behind the differential effects of IBP inhibitors on autophagic flux in MM cells.
• To investigate whether IBP inhibitor-induced autophagy is a protective or detrimental cellular response in MM.

Main Methods:

• Utilizing specific pharmacological inhibitors to target the IBP and autophagy pathways.
• Employing immunofluorescence microscopy to track protein trafficking and degradation.
• Assessing the impact of autophagy inhibition on the cytotoxicity of IBP inhibitors.

Main Results:

• IBP inhibition leads to a net increase in autophagy due to disrupted isoprenoid biosynthesis, an effect not seen with direct geranylgeranyl transferase inhibition.
• IBP inhibitor-induced autophagy acts as a cellular defense mechanism, as inhibiting autophagy enhances the cytotoxic effects of GGPP depletion.
• IBP inhibitors disrupt ER to Golgi trafficking of monoclonal light chain protein, which is not degraded via aggresomes or autophagosomes.

Conclusions:

• Disruption of the IBP induces a protective autophagic response in MM cells.
• Targeting specific components of the IBP, like GGTase II, holds promise for novel anti-myeloma therapies.
• Understanding the interplay between IBP inhibition and autophagy is crucial for optimizing MM treatment strategies.